A multiplex biosensor platform for the detection of breast cancer biomarkers

Our technology utilizes synthetic DNA designed to exclusively bind and sense specific target biomolecules. Our multiplex platform, a unique feature, consists of eight biosensors specifically targeting one breast cancer marker type. These markers, which are stage-dependent, along with diagnostic, prognostic, and predictive markers, represent a significant advancement in breast cancer diagnostics and subsequent care for cancer patients.
AinaTest Diagnostics is a startup created around university-based research assets. Our team is on a mission to develop a minimally invasive diagnostic device that detects several breast cancer markers in blood.
Since its establishment in 2024, AinaTest Diagnostics has been driven by a singular, powerful vision: to create a world with zero preventable deaths due to a lack of affordable and reliable breast cancer diagnostics. This vision is not just a goal, but a commitment that our team is dedicated to fulfilling.

Faculty Supervisor:

Yang Qu

Student:

Partner:

AinaTest Diagnostics Inc.

Discipline:

Physics

Sector:

Manufacturing

University:

University of New Brunswick

Program: